- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
PLAY BUTTON
PLAY BUTTON
33 Cards in this Set
- Front
- Back
|
(amount of drug)/(fluid compartment concentration)
|
Vd
|
|
protein bound drugs
liver and kidney disease pharmacodynamic variable altered? |
Vd
|
|
Vd eq
|
Vd = drug amount/drug concentration
|
|
Cl eq
|
Cl = elimination rate/[drug]
|
|
t1/2 eq
|
t1/2 = .7*Vd/Cl
|
|
10% remaining concentration
# half lives? |
3.3
|
|
12.5% remaining concentration
# half lives? |
3
|
|
25% remaining concentration
# half lives? |
2
|
|
Loading dose eq
|
Loading dose = Cp*Vd/F
|
|
Maintenance dose eq
|
Maintanence Dose = Cp*CL/F
Cp= target [drug] F = bioavailability |
|
change in loading dose with renal/hepatic disease
|
Unchanged
|
|
change in maintanence dose with renal/hepatic disease
|
lower
|
|
zero order elimination
constant __ of drug eliminated per time |
amount
|
|
first order elimination
constant __ of drug eliminated per time |
fraction
|
|
zero order elimitation
Cp decreases linearly/exponentially? |
linearly
|
|
first order elimination
Cp decreases linearly/exponentially? |
exponentially
|
|
Phase I metabolism
resulting metabolite characteritics |
slightly polar
water soluble often still active |
|
Phase I metabolism reactions
|
oxidation
reduction hydrolysis |
|
oxidation
reduction hydrolysis Phase? |
Phase I
|
|
cytochrome P-450
phase? |
Phase I
|
|
Phase II metabolism
resulting metabolite characteristics |
very polar
inactive *renally excreted |
|
Phase II metabolism reactions
|
acetylation
glucuronidation sulfanation |
|
acetylation
glucuronidation sulfanation Phase? |
Phase II
|
|
conjugation
Phase? |
Phase II
|
|
Phase metabolism lost in geriatrics
|
Phase I
|
|
competitive antagonist effect on agonist dose curve
|
shift to right
**decreased potency |
|
noncompetitive antagonist effect on agonist dose curve
|
shifts downward
**decreased efficacy |
|
EC50 vs Kd in system w/ spare receptors
|
EC50 < Kd
|
|
partial agonist vs full agonist
|
less efficacy
|
|
phase 1 clinical trial questions
|
is it safe?
pharmacokinetics? |
|
Phase 2 clinical trial questions?
|
does it work in patients?
|
|
Phase 3 clinical trial questions?
|
Does it work double blind?
|
|
Phase 4 clinical trial questions?
|
Postmarketing is it safe?
|
